Lumateperone辅助治疗重度抑郁症的研究
一项随机、双盲、安慰剂对照的多中心研究,以评估 Lumateperone 作为辅助疗法治疗重度抑郁症患者的疗效和安全性
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
The study will be conducted in three periods:
- Screening Period (up to 2 weeks) during which patient eligibility will be assessed.
- Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or lumateperone 42 mg/day in 1:1 ratio.
- Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 第三阶段
联系人和位置
学习联系方式
学习联系方式
- 姓名:Study Contact
- 电话号码:844-434-4210
- 邮箱:Participate-In-This-Study1@its.jnj.com
学习地点
-
-
-
Cherven Bryag、保加利亚、5980
- 招聘中
- Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
-
Kardzhali、保加利亚、6600
- 招聘中
- Medical Center Lifemed
-
Pleven、保加利亚、5800
- 招聘中
- Medical Center Medconsult-Pleven
-
Plovdiv、保加利亚、4004
- 招聘中
- Medical Center Mentalcare OOD
-
Sofia、保加利亚、1680
- 招聘中
- Medical Center Intermedica, OOD
-
Sofia、保加利亚、1510
- 招聘中
- Medical Center Hera EOOD
-
Sofia、保加利亚、1202
- 招聘中
- MHC - Sofia, EOOD
-
Sofia、保加利亚、1431
- 终止
- University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD
-
Stara Zagora、保加利亚、6003
- 完全的
- UMHAT Prof. Dr. St. Kirkovich AD
-
Varna、保加利亚、9020
- 招聘中
- Diagnostic Consulting Center Mladost - M Varna
-
-
-
-
-
Ahmedabad、印度、380008
- 暂停
- Ratandeep Surgical Hospital And Endoscopy Clinic
-
Ahmedabad、印度、380009
- 暂停
- Sushrusha Navneet Memorial Hospital
-
Ajmer、印度、305001
- 暂停
- J L N Medical College and Attached Hospitals
-
Bikaner、印度、334001
- 招聘中
- S P Medical College And Associated Group of Hospitals
-
Bārāmati、印度、413102
- 招聘中
- Baramati Hospital
-
Chandigarh、印度、160012
- 招聘中
- Post Graduate Institute of Medical Education And Research PGIMER
-
Guwahati、印度、781032
- 完全的
- Gauhati Medical College and Hospital
-
Kolhāpur、印度、416001
- 招聘中
- Swastik Hospital
-
Nagpur、印度、440001
- 招聘中
- KIMS-Kingsway Hospitals
-
Palsāna、印度、394315
- 招聘中
- Divyam Hospital
-
Pune、印度、411011
- 招聘中
- Shree Samarth Hospital
-
Rajkot、印度、360001
- 完全的
- Nagecha Hospital
-
Wardha、印度、442004
- 暂停
- Acharya vinoba bhave rural hospital
-
-
-
-
-
Belgrade、塞尔维亚、11000
- 招聘中
- University Clinical Center of Serbia
-
Belgrade、塞尔维亚、11000
- 招聘中
- Institute of Mental Health Serbia
-
Belgrade、塞尔维亚、11000
- 招聘中
- Clinical Center Dr Dragisa Misovic Dedinje
-
Kovin、塞尔维亚、26220
- 招聘中
- Special Hospital for Psychiatric Diseases Kovin
-
Kragujevac、塞尔维亚、34000
- 招聘中
- University Clinical Center Kragujevac
-
Kragujevac、塞尔维亚、34000
- 招聘中
- University Clinical Center Kragujevac 1
-
Niš、塞尔维亚、18000
- 招聘中
- University Clinical Center NIS 1
-
Niš、塞尔维亚、18000
- 招聘中
- University Clinical Center NIS
-
Novi Kneževac、塞尔维亚、23330
- 招聘中
- Special Hospital for Psychiatric Diseases Sveti Vracevi
-
-
-
-
-
Douai、法国、59500
- 招聘中
- Cabinet Medical des Drs Prizac-Desbonnet Scottez
-
Nantes、法国、44093
- 招聘中
- CHU de Nantes hotel Dieu
-
Nîmes、法国、30029
- 招聘中
- Hopital Caremeau
-
Paris、法国、75012
- 招聘中
- Groupe Hospitalier Pitie-Salpetriere
-
Poitiers、法国、86021
- 招聘中
- CH Henri Laborit
-
-
-
-
-
Kaunas、立陶宛、LT-44279
- 完全的
- Romuvos Klinika, JSC
-
Ziegzdriai、立陶宛、53136
- 完全的
- Kaunas Hospital of Lithuanian University of Health Sciences Psychiatric Clinic Mariu division
-
-
-
-
Alabama
-
Huntsville、Alabama、美国、35801
- 招聘中
- University of Alabama at Birmingham
-
-
California
-
Pico Rivera、California、美国、90660
- 招聘中
- CNRI-Los Angeles, LLC
-
-
Connecticut
-
Farmington、Connecticut、美国、06030
- 招聘中
- University of Connecticut Health Center
-
-
Florida
-
Clermont、Florida、美国、34711
- 终止
- Vertex Clinical Research
-
Hialeah、Florida、美国、33012
- 暂停
- New Life Medical Research Center, Inc.
-
Miami、Florida、美国、33122
- 招聘中
- Premier Clinical Research Institute
-
Miami、Florida、美国、33137
- 招聘中
- Miami Jewish Health System
-
Tampa、Florida、美国、33629
- 招聘中
- Interventional Psychiatry of Tampa Bay
-
-
Georgia
-
Atlanta、Georgia、美国、30329
- 招聘中
- The Emory Clinic
-
Decatur、Georgia、美国、30030
- 招聘中
- CenExeli Research LLC
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- 终止
- University of Kansas Medical Center Research Institute
-
Overland Park、Kansas、美国、66210
- 招聘中
- Collective Medical Research
-
-
Massachusetts
-
Methuen、Massachusetts、美国、01844
- 终止
- ActivMed Practices and Research
-
-
Missouri
-
O'Fallon、Missouri、美国、63368
- 招聘中
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River、New Jersey、美国、08755
- 招聘中
- Bio Behavioral Health
-
-
New York
-
Brooklyn、New York、美国、11235
- 招聘中
- SPRI Clinical Trials, LLC
-
New York、New York、美国、10036
- 招聘中
- Manhattan Behavioral Medicine
-
-
Ohio
-
Avon Lake、Ohio、美国、44012
- 招聘中
- Quest Therapeutics of Avon Lake
-
Cincinnati、Ohio、美国、45219
- 招聘中
- University of Cincinnati Medical Center
-
Columbus、Ohio、美国、43210
- 招聘中
- The Ohio State University
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- University of Pennsylvania - Perelman School of Medicine
-
-
Texas
-
Houston、Texas、美国、77081
- 招聘中
- DM Clinical Research
-
Mansfield、Texas、美国、76063
- 完全的
- Hawkins Psychiatry, PC
-
Richardson、Texas、美国、75080
- 招聘中
- Pillar Clinical Research, LLC
-
-
Washington
-
Bellevue、Washington、美国、98007
- 招聘中
- Northwest Clinical Research Center
-
-
-
-
-
Barcelona、西班牙、08036
- 招聘中
- Hosp. Clinic de Barcelona
-
Barcelona、西班牙、08035
- 招聘中
- Hosp Univ Vall D Hebron
-
Madrid、西班牙、28034
- 完全的
- Hosp. Univ. Ramon Y Cajal
-
Sabadell、西班牙、08208
- 招聘中
- Hosp.Univ.Parc Tauli
-
Zamora、西班牙、49021
- 招聘中
- Hosp. Prov. de Zamora
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Male or female patients between the ages of 18 and 65 years, inclusive;
-
Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) and meets all of the following criteria:
- The start of the current major depressive episode (MDE) is at least 12 weeks but not more than 18 months prior to Screening;
- Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;
- Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline;
- Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline;
- Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.
-
Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ) and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:
- citalopram/escitalopram
- fluoxetine
- paroxetine
- sertraline
- duloxetine
- levomilnacipran/milnacipran (if locally approved for MDD)
- venlafaxine/desvenlafaxine
- bupropion
- vilazodone
- vortioxetine
Exclusion Criteria:
-
Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
- Bipolar Disorder;
-
Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:
- Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment;
- Eating disorder;
- Substance use disorders (excluding nicotine);
- Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;
- Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
-
The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;
-
The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;
-
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:
- At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
- At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;
- At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or
- The patient is considered to be in imminent danger to him/herself or others.
-
The patient has a first MDE at age 60 years or older.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
安慰剂比较:安慰剂
|
Matching capsules administered orally, once daily |
|
实验性的:Lumateperone 42 毫克
|
Lumateperone 42 mg capsules administered orally, once daily |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Montgomery-Asberg Depression Rating Scale
大体时间:Day 43
|
The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms. |
Day 43
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Clinical Global Impression Scale-Severity
大体时间:Day 43
|
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). |
Day 43
|
合作者和调查者
调查人员
调查人员
- 研究主任:Intra-Cellular Therapies, Inc. Clinical Trial、Intra-Cellular Therapies, Inc.
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- ITI-007-505
- ITI-007-505 (其他标识符:Janssen Research & Development, LLC)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.